Trazimera Purple Book BLA 761081

BLA number
761081
Proprietary names
Trazimera
Proper names
trastuzumab-qyyp
Applicant
Pfizer Ireland Pharmaceuticals Unlimited Company
Center
CDER
First observed release
2020-02-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Trazimeratrastuzumab-qyyp351(k) Biosimilar420MGFor InjectionIntravenousMulti-Dose VialRxLicensed2019-03-11
002Trazimeratrastuzumab-qyyp351(k) Biosimilar150MGFor InjectionIntravenousMulti-Dose VialRxLicensed2020-11-30

Reference Biological Product#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
103792Herceptintrastuzumab351(a)Disc*2026-06-01

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2026-04-01U001Trazimera351(k) BiosimilarRxPfizer Ireland Pharmaceuticals Unlimited Company
2026-04-01U002Trazimera351(k) BiosimilarRxPfizer Ireland Pharmaceuticals Unlimited Company
2022-03-01U002Trazimera351(k) BiosimilarRxPfizer Ireland Pharmaceuticals
2020-11-01N002Trazimera351(k) BiosimilarRxPfizer Ireland Pharmaceuticals

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-11-01002Trazimera351(k) BiosimilarRxLicensed2020-11-30
2020-05-01001Trazimera351(k) BiosimilarRxLicensed2019-03-11
2020-02-01001Trazimera351(k) BiosimilarLicensed2019-03-11